Merck rose nearly 7% as its new antithrombotic drug is expected to be approved by FDA

The stock price of us pharmaceutical giant Merck (NYSE: MRK) rose nearly 7% on Monday, hitting a new high since its IPO Its antithrombotic drug, vorapaxar, is expected to get FDA approval, boosting its share price The food and Drug Administration will review vorapaxar on Wednesday As the results of the clinical trials of vorapaxar are satisfactory, it is highly likely that FDA will finally approve its marketing Vorapaxar is designed to prevent heart attacks and strokes Boosted by the positive news, Merck pharmaceutical shares rose 6.46% to close at $53.10 The share price rose to $53.44, a new high since its IPO At Monday's closing price, it has a market value of $160.302 billion Merck has invested $8 billion in research and development of vorapaxar, and hopes that vorapaxar will be licensed to prevent recurrence in patients with first-time heart disease It has been very difficult to approve heart disease drugs Tredaptive, another new cardiovascular drug of Merck, has been denied by FDA.